Delving into the Latest Updates on Kanglaite with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

KLT, KLTc, KLTi

+ [2]

Target-

Mechanism

Apoptosis stimulants, Cell cycle inhibitors

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [1]

Active Indication

CachexiaLiver CancerNon-Small Cell Lung Cancer

Inactive Indication

Advanced Pancreatic Adenocarcinomametastatic non-small cell lung cancerProstatic Cancer

Originator Organization

Zhejiang Kanglaite Pharmaceutical Co., Ltd.

Active Organization

Zhejiang Kanglaite Pharmaceutical Co., Ltd.

Inactive Organization

Kanglaite USA, Inc.

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1997),

Liver CancerNon-Small Cell Lung Cancer

Regulation-

Login to view timeline

CONTEXTChinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.OBJECTIVETo assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP).MATERIALS AND METHODSRandomized controlled trials (RCTs) were searched in databases including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science from inception to September 2023. We calculated the risk ratio with a 95% confidence interval and the surface under the cumulative ranking area curve (SUCRA) for the clinical efficacy rate (CER), the efficacy rate by Karnofsky Performance Status (KPS), and the rates of leukopenia reduction (LRR) and gastrointestinal reactions (GRR).RESULTSForty-seven RCTs were included, including nine CMI types: Aidi, Fufangkushen, Huangqi, Kangai (KA), Kanglaite (KLT), Renshenduotang, Shenqifuzheng (SQFZ), Shenmai (SM), and Yadanzi. KLT and KA were likely optimal choices with radiotherapy for CER and KPS, respectively. KA and KLT were optimal choices with RT + DDP for CER and GRR, respectively. KLT was the likely optimal choice with RT + DP for CER and KA for both KPS and GRR. SM and SQFZ were the likely optimal choices with RT + TP for CER and LRR, respectively.CONCLUSIONSThe optimal recommendation depends on whether CMIs are used with radiotherapy or concurrent chemoradiotherapy. More high-quality RCTs are needed to confirm further and update the existing evidence.

01 Dec 2023·Integrative Medicine Research

Chinese herbal injections in combination with radiotherapy for advanced pancreatic cancer: A systematic review and network meta-analysis

Review

Author: Fan, Bing-Bing ; Ma, Yin-Jie ; Robinson, Nicola ; Zhao, Ruo-Tong ; Liu, Jian-Ping ; Wang, Xue-Hui ; Xu, Yi-Fang ; Chen, Yun-Ru ; Huang, Yu-Bei ; Hu, Shao-Bo ; Liu, Zhao-Lan ; Zhou, Yan-Ji

BackgroundAdvanced pancreatic cancer (APC) is a fatal disease with limited treatment options. This study aims to evaluate the effectiveness and safety of different Chinese herbal injections (CHIs) as adjuvants for radiotherapy (RT) in APC and compare their treatment potentials using network meta-analysis.MethodsWe systematically searched three English and four Chinese databases for randomized controlled trials (RCTs) from inception to July 25, 2023. The primary outcome was the objective response rate (ORR). Secondary outcomes included Karnofsky performance status (KPS) score, overall survival (OS), and adverse events (AEs). The treatment potentials of different CHIs were ranked using the surface under the cumulative ranking curve (SUCRA). The Cochrane RoB 2 tool and CINeMA were used for quality assessment and evidence grading.ResultsEighteen RCTs involving 1199 patients were included. Five CHIs were evaluated. Compound Kushen injection (CKI) combined with RT significantly improved ORR compared to RT alone (RR 1.49, 95 % CrI 1.21-1.86). Kanglaite (KLT) plus RT (RR 1.58, 95 % CrI 1.20-2.16) and CKI plus RT (RR 1.49, 95 % CrI 1.16-1.95) were associated with improved KPS score compared to radiation monotherapy, with KLT+RT being the highest rank (SUCRA 72.28 %). Regarding AEs, CKI plus RT was the most favorable in reducing the incidence of leukopenia (SUCRA 90.37 %) and nausea/vomiting (SUCRA 85.79 %).ConclusionsCKI may be the optimal choice of CHIs to combine with RT for APC as it may improve clinical response, quality of life, and reduce AEs. High-quality trials are necessary to establish a robust body of evidence.Protocol registrationPROSPERO, CRD42023396828.

01 Sep 2023·Journal of cancer research and clinical oncology

Network meta-analysis of 8 types of traditional Chinese medicine injection combined with chemotherapy in colorectal cancer treatment.

Review

Author: Zhang, Kun ; Gao, Wenguang

OBJECTIVEThis study conducted a network meta-analysis to comprehensively compare the efficacy and safety of 8 types of traditional Chinese medicine injection combined with chemotherapy in colorectal cancer treatment.METHODSWe searched relevant previous studies from databases including Pubmed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Service System (SinMed), VIP, and Wanfang Database. The searched studies spanned from the inception of databases to December 2022. The included randomized controlled trials were screened; data were extracted; and bias risk was assessed. The network meta-analysis was performed using Revman 5.4 software, R software, and STATA software.RESULTSFifty randomized controlled studies were included, including 8 types of traditional Chinese medicine injection. The results showed that Aidi injection [OR 1.65,95%CI (1.33,2.05)], compound Kushenshen injection [OR 2.72,95%CI (2.12,3.51)], Kangai injection [OR 2.16,95%CI (1.56,3.02)], and Shenqi Fuzheng injection [OR 1.97,95%CI (1.24,3.15)] combined with chemotherapy in colorectal cancer treatment had a significantly higher objective response rate (p < 0.05) than single chemotherapy, and compound Kushen injection + chemotherapy [OR 2.72,95%CI (2.12,3.51)] regimen ranked the highest. The disease control rate of Aidi injection, Brucea javanica oil emulsion injection [OR 4.1,95%CI (1.74,10.43)], compound Kushen injection [OR 2.43,95%CI (1.73,3.44), Kangai injection[OR 2.31,95%CI (1.51,3.58)], Kanglaite injection[OR 3.18,95%CI (1.52,6.9)], and Shenqi Fuzheng injection[OR 2.6,95%CI (1.22,5.92)] combined with chemotherapy in the treatment of colorectal cancer was significantly improved (p < 0.05), and Brucea javanica oil emulsion injection + chemotherapy[OR 4.1,95%CI (1.74,10.43)] regimen ranked the highest. The incidence of leukopenia reduction in the treatment of colorectal cancer was significantly reduced by Aidi injection[OR 0.32,95%CI (0.24,0.43)], Brucea javanica oil emulsion injection [OR 0.34,95%CI (0.17,0.68)] compound Kushen injection [OR 0.27,95%CI (0.17,0.40)], Kangai injection [OR 0.23,95%CI (0.14,0.37)], and Kanglaite injection [OR 0.20,95%CI (0.09,0.45)] combined with chemotherapy (p < 0.05), and Kanglaite injection + chemotherapy [OR 0.20,95%CI (0.09,0.45)] regimen ranked the highest. Aidi injection [OR 0.48,95%CI (0.3,0.74)], Brucea javanica oil emulsion injection [OR 0.09,95%CI (0.01,0.43)], and Kangai injection [OR 0.47,95%CI (0.22,0.96)] combined with chemotherapy in the treatment of colorectal cancer significantly reduced the incidence of thrombocytopenia reduction (p < 0.05), and Brucea javanica oil emulsion injection + chemotherapy [OR 0.09,95%CI (0.01,0.43)] regimen ranked the highest. Aidi injection [OR 0.49,95%CI (0.32, 0.74)], Kangai injection [OR 0.26,95%CI (0.09,0.71)] combined with chemotherapy in the treatment of colorectal cancer significantly reduced the incidence of hemoglobin reduction (p < 0.05), and Kangai injection + chemotherapy [OR 0.26,95%CI (0.09,0.71)] regimen ranked the highest. Aidi injection [OR 0.38,95%CI (0.28,0.52)], compound Kushen injection [OR 0.23,95%CI (0.15,0.36)] and Kangai injection [OR 0.19,95%CI (0.12,0.30)] combined with chemotherapy in the treatment of colorectal cancer significantly reduced the incidence of nausea and vomiting (p < 0.05), and Kangai injection + chemotherapy[OR 0.19,95%CI (0.12,0.30)] regimen ranked the highest. Aidi injection [OR 0.51,95%CI (0.35,0.74)], compound Kushenshen injection [OR 0.27,95%CI (0.15,0.47)], and Kanglaite injection [OR 0.31,95%CI (0.13,0.69)] combined with chemotherapy in the treatment of colorectal cancer significantly reduced the incidence of abdominal pain and diarrhea (p < 0.05), and compound Kushen injection + chemotherapy [OR 0.27,95%CI (0.15,0.47)] regimen ranked the highest.CONCLUSIONAidi injection, Brucea javanica oil emulsion injection, compound Kushen injection, Kangai injection, Shenqi Fuzheng injection, Kanglaite injection, Shenfu injection, and Xiaoaiping injection combined with chemotherapy functioned more effectively than single chemotherapy did in colorectal cancer treatment. Nevertheless, limited by the treatment quality and methodology of different intervention measures included in the study, this conclusion is expected to be scrutinized in higher-quality and rigorously designed randomized controlled trials. PROSPERO registration No.: CRD42023392398.

100 Deals associated with Kanglaite

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cachexia	CN	Zhejiang Kanglaite Pharmaceutical Co., Ltd.	16 Dec 1997
Liver Cancer	CN	Zhejiang Kanglaite Pharmaceutical Co., Ltd.	01 Jan 1997
Non-Small Cell Lung Cancer	CN	Zhejiang Kanglaite Pharmaceutical Co., Ltd.	01 Jan 1997

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
metastatic non-small cell lung cancer	Phase 1	US	Kanglaite USA, Inc.	01 May 2012
Prostatic Cancer	Phase 1	US	Kanglaite USA, Inc.	01 Nov 2011
Advanced Pancreatic Adenocarcinoma	Discovery	US	Kanglaite USA, Inc.	01 Aug 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03101514 (CTgov)	Phase 2	Head and Neck Neoplasms	53	chemotherapy+Kanglaite	pedoudgumj(djrzlrrxba) = bkcgozlhkv wtuqhqkmcz (mjhegjclwx, hfogtlbqab - eoihbfrrde) View more	-	23 Jun 2021
ASCO2011	Phase 2	Secondary malignant neoplasm of pancreas	58	Kanglaite Injection (KLT) + Gemcitabine hydrochloride (GEM)	(qdcvwfbywc) = rzturqglxd ojhmnirrzi (rvucdqxdkl )	Positive	20 May 2011